Pathogenic mechanism of recurrent mutations of SCN8A in epileptic encephalopathy by Wagnon, J.L. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/168024
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
RESEARCH ARTICLE
Pathogenic mechanism of recurrent mutations of SCN8A in
epileptic encephalopathy
Jacy L. Wagnon1, Bryan S. Barker2, James A. Hounshell2, Charlotte A. Haaxma3, Amy Shealy4,
Timothy Moss4, Sumit Parikh5, Ricka D. Messer6, Manoj K. Patel2 & Miriam H. Meisler1
1Department of Human Genetics, University of Michigan, Ann Arbor, Michigan
2Department of Anesthesiology and Neuroscience Graduate Program, University of Virginia Health System, Charlottesville, Virginia
3Department of Pediatric Neurology, Radboud University, Nijmegen, The Netherlands
4Cleveland Clinic Genomic Medicine Institute, Cleveland, Ohio
5Department of Pediatric Neurology, Cleveland Clinic, Cleveland, Ohio
6Department of Pediatric Neurology, Johns Hopkins Medical Institute, Baltimore, Maryland
Correspondence
Miriam H. Meisler, 4909 Buhl, University of
Michigan, Ann Arbor, MI 48109-5618.
Tel: 734-763-5546; Fax: 734-763-9691;
E-mail: meislerm@med.umich.edu
Funding Information
This work was supported by the National
Institutes of Health (NIH) grants R01-
NS34509 (to M. H. M.) and R01-NS075157
(to M. K. P.). J. L. W. is recipient of a
postdoctoral fellowship from the Dravet
Syndrome Foundation.
Received: 20 October 2015; Accepted: 20
November 2015
Annals of Clinical and Translational
Neurology 2016; 3(2): 114–123
doi: 10.1002/acn3.276
Abstract
Objective: The early infantile epileptic encephalopathy type 13 (EIEE13, OMIM
#614558) results from de novo missense mutations of SCN8A encoding the
voltage-gated sodium channel Nav1.6. More than 20% of patients have recur-
rent mutations in residues Arg1617 or Arg1872. Our goal was to determine the
functional effects of these mutations on channel properties. Methods: Clinical
exome sequencing was carried out on patients with early-onset seizures, devel-
opmental delay, and cognitive impairment. Two mutations identified here,
p.Arg1872Leu and p.Arg1872Gln, and two previously identified mutations,
p.Arg1872Trp and p.Arg1617Gln, were introduced into Nav1.6 cDNA, and
effects on electrophysiological properties were characterized in transfected ND7/
23 cells. Interactions with FGF14, G-protein subunit Gbc, and sodium channel
subunit b1 were assessed by coimmunoprecipitation. Results: We identified two
patients with the novel mutation p.Arg1872Leu and one patient with the recur-
rent mutation p.Arg1872Gln. The three mutations of Arg1872 and the mutation
of Arg1617 all impaired the sodium channel transition from open state to inac-
tivated state, resulting in channel hyperactivity. Other observed abnormalities
contributing to elevated channel activity were increased persistent current,
increased peak current density, hyperpolarizing shift in voltage dependence of
activation, and depolarizing shift in steady-state inactivation. Protein interac-
tions were not affected. Interpretation: Recurrent mutations at Arg1617 and
Arg1872 lead to elevated Nav1.6 channel activity by impairing channel inactiva-
tion. Channel hyperactivity is the major pathogenic mechanism for gain-of-
function mutations of SCN8A. EIEE13 differs mechanistically from Dravet syn-
drome, which is caused by loss-of-function mutations of SCN1A. This distinc-
tion has important consequences for selection of antiepileptic drugs and the
development of gene- and mutation-specific treatments.
Introduction
Early infantile epileptic encephalopathy type 13 (EIEE13,
OMIM # 614558) is a newly recognized syndrome caused
by de novo missense mutations of SCN8A. Clinical fea-
tures include seizure onset before 18 months of age, intel-
lectual disability, and developmental delay.1–5 Movement
disorders are common and 50% of affected individuals
are nonambulatory.1,3,6–12 SUDEP (sudden unexpected
death in epilepsy) is reported in 10% of cases.1,2,4,5
SCN8A encodes the pore-forming voltage-gated sodium
channel subunit Nav1.6, which is widely expressed in neu-
rons of the CNS and PNS.13 Nav1.6 is concentrated at the
axon initial segment and at nodes of Ranvier.14,15 Nav1.6
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is composed of four homologous domains with six trans-
membrane segments each, and the cytoplasmic N-term-
inal and C-terminal domains (Fig. 1A).
Two amino acid residues, Arg1617 and Arg1872, are
the sites of mutation in 20% of EIEE13. Arg1617 is
located in the voltage-responsive S4 transmembrane seg-
ment of domain IV (Fig. 1A). The substitution
p.Arg1617Gln has occurred in five unrelated individu-
als.1–3,16,17 Arg1872 is located in the cytoplasmic C-term-
inal domain (Fig. 1A). Two missense mutations of
Arg1872 were described in seven patients1,3,11,18 and we
describe a third substitution in two patients, making this
the most frequently mutated residue. The CpG dinu-
cleotides in the codons for Arg1617 and Arg1872 are
mutational hotspots (Fig. 1B). Recurrence in unrelated
patients and absence from unaffected individuals (http://
exac.broadinstitute.org) provides strong evidence that
these mutations are pathogenic. Our data demonstrate
that these mutations result in impaired channel inactiva-
tion that underlies neuronal hyperexcitability and sei-
zures.
Material and Methods
Clinical exome sequencing
The c.5615G>T mutation (p.Arg1872Leu) in Case 1 was
identified by whole exome sequencing at the Genomic
Medicine Institute at the Cleveland Clinic (Cleveland,
OH, USA). The c.5615G>T mutation (p.Arg1872Leu) in
Case 2 was identified by whole exome sequencing at the
Johns Hopkins Medical Institute (Baltimore, MD, USA).
The c.5615G>A mutation (p.Arg1872Gln) in Case 3 was
identified in the clinical exome sequencing laboratory at
Radboud University (Nijmegen, the Netherlands).
Standard protocol approvals, registrations,
and patient consents
An institutional review board (IRB) approval was
obtained and the parent or legal guardian of each patient
gave informed consent.
Site-directed mutagenesis of the Nav1.6
cDNA and C-terminal constructs
The amino acid substitutions p.Arg1617Gln,
p.Arg1872Leu, and p.Arg1872Trp were introduced into
the tetrodotoxin (TTX)-resistant derivative of the full-
length Nav1.6 cDNA clone
19 as described previously.4
Site-directed mutagenesis was carried out with the Quik-
Change II XL kit (Agilent Technologies, Santa Clara, CA,
USA). The entire 6-kb open reading frame was sequenced
to confirm the absence of other mutations.
The pHA-Nav1.6-CT cDNA construct containing the
213 amino acid C-terminal domain of Nav1.6 with an N-
terminal HA epitope tag20 was kindly provided by Dr.
David Ornitz, Washington University. The substitution
p.Arg1872Trp was introduced as above and the open
reading frame was completely sequenced.
Plasmids encoding sodium channel–
interacting proteins
The sodium channel b subunit cDNA construct pNavb1-
EYFP was kindly provided by Dr. Jeanne Nerbonne.21
The fibroblast growth factor 14 cDNA construct pFGF14-
1b-myc tag was a gift from Dr. David Ornitz.22 Plasmids
pGb2IRES-YFP and pGc3IRES-cyan encoding the G-pro-
tein subunits Gb2 and Gc3 were kindly provided by Dr.
Massimo Mantegazza.23
Cell culture
DRG-neuron–derived ND7/23 cells (Sigma Aldrich, St.
Louis, MO, USA) were grown in a humidified atmo-
sphere of 5% CO2 and 95% air at 37°C in Dulbecco’s
Modified Eagle’s Medium (DMEM, 1X) supplemented
with 10% fetal bovine serum (FBS), non-essential amino
acids (NEAA) and sodium pyruvate. Cells were plated
onto Petri dishes 48 h prior to transfection and trans-
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Figure 1. Recurrent mutations of arginine residues 1617 and 1872 in
SCN8A. (A) Four-domain structures of the voltage-gated sodium
channel a subunit. The positions of the recurrently mutated residues
Arg1617 (the outermost charged residue in the S4 transmembrane
segment of domain IV) and Arg1872 (near the middle of the
cytoplasmic C-terminal domain) are shown. (B) CpG mutation hot
spots in the codons for Arg1617 and Arg1872.
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fected for 5 h in non-supplemented DMEM using Lipofec-
tamine 3000 according to the manufacturer’s instruction
(Life Technologies, Carlsbad, CA, USA) with 5 lg of
Nav1.6 a subunit cDNA and 0.5 lg of the fluorescent
m-Venus bioreporter. Electrophysiological recordings of
fluorescent cells were made 48 h after transfection.
Electrophysiology
Recordings were carried out in the presence of 500 nmol/
L TTX to block endogenous sodium currents in the neu-
ron-derived ND7/23 cells. Currents were recorded using
the whole-cell configuration of the patch clamp recording
technique as described previously.24 The intracellular
recording solution contained (in mmol/L): 140 CsF, 2
MgCl2, 1 EGTA, 10 HEPES, 4 Na2ATP, 0.3 NaGTP (pH
adjusted to 7.3 with CsOH, osmolarity adjusted to 290
mOsm with sucrose). Cultured ND7/23 cells were bathed
in solution containing (in mmol/L): 130 NaCl, 4 KCl, 1
CaCl2, 5 MgCl2, 5 HEPES, 5 Glucose (pH adjusted to 7.4
with NaOH, osmolarity adjusted to 300 mOsm with
sucrose). Experiments were performed at room tempera-
ture (20–22°C). After establishing whole cell, a minimum
series resistance compensation of 75% was applied.
Capacitive and leak currents were subtracted using the P/
N-4 protocol for all experiments, except steady-state inac-
tivation protocols. The current–voltage relationship was
determined using a 100-msec voltage pulse from 80 to
+70 mV in steps of 5 mV from a holding potential of
120 mV at 2 sec intervals. Conductance as a function
of voltage was derived from the current–voltage relation-
ship and fitted by a Boltzmann function as described pre-
viously.24 Decays of macroscopic currents were fitted to a
single exponential function and time constants were
determined.25 For steady-state inactivation, neurons were
held at 120 mV and test potentials from 115 mV to
10 mV for 1 sec at 5 mV increments were applied. The
second pulse to 10 mV for 40 msec was used to assess
channel availability. Currents during the second pulse
were normalized for each cell with the largest current as
1.0 and fit to the Boltzmann function. For recovery from
inactivation, neurons were held at 120 mV and depolar-
ized to a test potential of 0 mV for 1 sec to inactivate the
Na channels. Recovery was determined at times between
1 msec and 60 sec at a test potential of 90 mV. A
40 msec pulse to 10 mV was subsequently applied to
assess the extent of channel recovery. For each cell, cur-
rent amplitudes during this test pulse were normalized so
that the largest current during the conditioning potential
was 1.0. Data were fit to a double exponential function:
y ¼ A1ð1 exp½t=T1Þ þ A2ð1 exp½t=T2Þ
where A1 and A2 are the coefficients for the fast and slow
exponentials, t is the time (in msec), and Ƭ1 and Ƭ2 are
the fast and slow time constants, respectively.
Coimmunoprecipitation and western
blotting
HEK293 cells were transfected with 3 lg of cDNA encod-
ing the C-terminal domain of Nav1.6 and 3 lg of the test
construct. Cell extracts were prepared and immunoprecip-
itated as described previously.26 Cells were lysed in 1 mL
of buffer containing 20 mmol/L Tris-HCl, pH 7.5,
137 mmol/L NaCl, and 1% NP-40 with protease inhibi-
tors (Roche complete mini, EDTA-free, Indianapolis, IN,
USA). Lysates were incubated with 20 lL anti-HA anti-
body-coated agarose beads (sc-7392AC, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) overnight at 4°C.
Immune complexes on the beads were washed four times
and eluted by boiling in 2X electrophoresis sample buffer
at 95°C for 5 min. Western blotting was carried out as
described previously.27 Blots were immunostained with
rabbit polyclonal anti-HA (H6908, Sigma Aldrich), rabbit
polyclonal anti-GFP (G1544, Sigma Aldrich), rabbit poly-
clonal anti-myc (C3956, Sigma Aldrich), or rabbit poly-
clonal anti-Gb2 (sc-380, Santa Cruz Biotechnology).
Results
Clinical features of three patients with
mutations of arginine 1872
The clinical features of three new cases are summarized in
Table 1. All three patients were born after full-term preg-
nancies. Clinical exome sequencing identified the
heterozygous mutation c.5615G>T resulting in the novel
amino acid substitution p.Arg1872Leu in patients 1 and
2. Patient 3 carried the SCN8A mutation c.5615G>A
resulting in the amino acid substitution p.Arg1872Gln.
None of the mutations were present in either parent,
demonstrating de novo origin.
The features of these patients are consistent with the
recently described clinical spectrum of SCN8A encephalo-
pathy.1 Two patients exhibited very early onset at 2 and
6 weeks of age. Sodium channel blockers were partially
effective (Table 1). Detailed clinical histories are provided
as an Appendix.
Functional effects of mutations in arginine
residue 1872
Arginine residue 1872 is located near the center of the
cytoplasmic C-terminal domain of Nav1.6 (Fig. 1A).
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This site was implicated in direct interaction with the
inactivation gate of the channel, mediated by interac-
tion between positively and negatively charged resi-
dues.28,29 Loss of the positive charge of arginine residue
1872 is therefore predicted to impair channel inactiva-
tion.
Patient mutations substituting leucine, glutamine, or
tryptophan for arginine 1872 were introduced into the
full-length Nav1.6 cDNA, which was transfected into
the neuron-derived cell line ND7/23. Representative
currents from ND7/23 cells transfected with wild-type
(WT) and mutant Nav1.6 channels are shown in Fig-
ure 2A. Peak current density was elevated for
p.Arg1872Trp, but was not significantly changed for
p.Arg1872Leu or p.Arg1872Gln (Fig. 2B, Table 2). To
determine the kinetics of open state inactivation,
macroscopic current decay was fit to single exponential
functions and the fast time constant (sfast) was plotted
as a function of voltage. Transition from open state to
the inactivated state was significantly delayed by all
three mutations (Fig. 2C), consistent with prediction.
The slowing of fast inactivation is evident when the
peaks of the current traces are aligned so that inactiva-
tion kinetics can be compared directly (Fig. 2D).
At 100 msec after stimulus, p.Arg1872Leu exhibited
elevated persistent current normalized to the peak of the
macroscopic current (Ipersistent/Ipeak) (Fig. 2E, Table 2).
Ramp currents evoked using a slow ramp stimulus did
not differ from WT for any of the mutants (data not
shown).
Analysis of steady-state kinetics demonstrates that
p.Arg1872Leu and p.Arg1872Gln cause a small but signifi-
cant hyperpolarizing shift in the voltage dependence of
activation (P < 0.05) (Fig. 2F, Table 2). In addition,
p.Arg1872Gln caused a depolarizing shift in steady-state
inactivation (Fig. 2G, Table 2). The values for the slope
(k) were unchanged.
Functional effects of the recurrent mutation
p.Arg1617Gln
Arginine residue 1617 is the outermost positively charged
residue in the voltage-responsive transmembrane segment
DIV-S4 and is implicated in coupling of channel activa-
tion with subsequent inactivation.
Representative currents from ND7/23 cells transfected
with the p.Arg1617Gln mutant of Nav1.6 are shown in Fig-
ure 3A. Peak current densities for p.Arg1617Gln were not
different from WT (Fig. 3B). A profound change in the
kinetics of transition from open state to the inactivated
state was observed. At voltages above 20 mV, the WT
channel exhibits faster decay time constants with increasing
depolarizing voltage steps, but this response is missing for
p.Arg1617Gln (Fig. 3C). Sample traces reveal the striking
difference in current decay between WT and mutant
channel (Fig. 3D). The apparent uncoupling of activation
to fast inactivation likely accounts for the large increase in
persistent current from 1% of peak transient current for
the WT channels to 6% of peak transient current for the
p.Arg1617Gln channels (Fig. 3E). The elevation of persis-
tent current is evident in the ratio of persistent current to
peak current for p.Arg1617Gln (Table 2).
The inactivation parameters for p.Arg1617Gln were
significantly shifted in the depolarizing direction and
the value of the slope was increased, demonstrating dis-
ruption in the normal process of channel inactivation
(Fig. 3G, Table 2). The difference in the extent of inac-
tivation at 45 mV is shown in Figure 3H. There was
Table 1. Clinical features of three new patients with amino acid substitution of arginine residue 1872.
Patient (sex) 1 (F) 2 (F) 3 (M)
Amino acid substitution p.Arg1872Leu p.Arg1872Leu p.Arg1872Gln
Seizure onset 2 weeks 6 weeks 4 months
Current age 17 years 1.5 years 2 years
Seizure types GTC GTC with apnea GTC, A, T with bradycardia, SE
Development and
motor abnormalities
Walking at 12-15 months, then
regression with hypotonia
progressing to hypertonia
and quadriplegia
Sat 12 months, hypotonia Speech arrest 10 months,
sat 13 months,
walked 16 months
Intellectual disability Severe Moderate Severe
EEG Generalized slowing, severe
diffuse encephalopathy
Normal Diffuse encephalopathy
MRI Cerebella and cerebral atrophy Normal Bilateral flat insular cortex
Drug response PHT and VNS partially effective TPM and LEV temporarily
effective, OXC, LTG, VPA,
and CLN effective
ZNS and LEV temporarily effective,
PHT and LEV effective
A, absence; CLN, clonazepam; GTC, generalized tonic-clonic; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; PHT, phenytoin; SE, sta-
tus epilepticus; T, tonic, TPM, topiramate; VNS, vagus nerve stimulator; VPA, valproate; ZNS, zonisamide.
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also a small hyperpolarizing shift in the voltage depen-
dence of activation (Fig. 3F, Table 2).
Protein interactions with the C-terminal
domain of Nav1.6
In addition to its role in channel inactivation, the
C-terminal domain of Nav1.6 interacts with several
proteins that regulate channel trafficking or activity.20,23,30
To determine whether mutations at Arg1872 disrupt these
interactions, we tested the effect of the p.Arg1872Trp
mutation with substitution of the large uncharged trypto-
phan residue.
HEK cells were cotransfected with cDNAs encoding the
HA-tagged WT or mutant C-terminal fragment of Nav1.6
and cDNAs encoding the G-protein subunits Gb2 and
Figure 2. Biophysical effects of missense mutations at residue Arg1872 in Nav1.6. (A) Representative traces of families of Na currents from ND7/
23 cells transfected with the indicated Nav1.6 cDNAs. (B) Averaged current–voltage (I-V) relation for cells expressing WT and mutant Nav1.6. Peak
currents were normalized to cell capacitance. (C) Average fast time constant obtained from single exponential fits to macroscopic current decays
as a function of voltage (mV). (D) Representative traces of normalized currents evoked by a 20 mV stimulus from a holding potential of
120 mV illustrate delays in macroscopic current decay. (E) Representative normalized current traces recorded during a 100-msec depolarizing
pulse from 120 mV to 0 mV illustrating the presence of elevated persistent sodium current for p.Arg1872Leu. (F) Voltage dependence of
channel activation. (G) Voltage dependence of steady-state inactivation. Smooth lines correspond to the least squares fit when average data were
fit to a single Boltzmann equation. Data are mean  SEM. Statistical significance: *P < 0.05. Black, wild type; red, p.Arg1872Leu; orange,
p.Arg1872Gln; green, p.Arg1872Trp.
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Gc3. Lysates were incubated with anti-HA-coated beads
and bound proteins were eluted and examined by western
blotting. The yield of Gb2 was comparable with mutant
and WT C-terminus (Fig. S1A). Similarly, the mutation
did not impair binding of the sodium channel b1 subunit
(Fig. S1B) and the fibroblast growth factor isoform
FGF14b (Fig. S1C).
Discussion
Unlike protein termination mutations, the pathogenic
impact of missense mutations is difficult to predict
without functional tests. Due in part to the multiple
intramolecular interactions within the sodium channel a
subunit,31,32 substitution of a single amino acid often
has multiple effects on sodium channel function.
Mutations at Arg1872 and Arg1617 impair
channel inactivation by different
intramolecular mechanisms
The three allelic mutations that eliminate the positively
charged residue Arg1872 from the C-terminus of Nav1.6
all result in a significant delay in transition from the open
state to the inactivated state. This observation is consis-
tent with previous studies demonstrating a direct role of
the C-terminal domain in fast inactivation.29,33 Interac-
tion of the C-terminus of sodium channel Nav1.5 with its
inactivation gate was shown to stabilize the inactivated
state.31,34 Exchange of C-terminal domains between
sodium channels Nav1.2, Nav1.5, and Nav1.6 results in
partial transfer of inactivation properties.28,33 The interac-
tion between the C-terminus and the inactivation gate
appears to involve electrostatic interactions, since inacti-
vation of Nav1.2 was slowed by reversing the charge of
Glu1880 (corresponding to Glu1870 in Nav1.6) by
replacement with lysine.29 These data support the view
that loss of the positively charged residue arginine 1872
destabilizes interaction with the inactivation gate and
delays entry into the inactivated state. This is predicted to
increase the fraction of channels that can reopen during
sustained depolarization, resulting in increased channel
activity and epileptogenic persistent current. The different
effects on current density and channel kinetics of these
allelic substitutions can be related to the chemical struc-
ture of the substituted residue. Substitution of the corre-
sponding arginine residue of Nav1.2 by leucine or
glutamine also results in epileptic encephalopathy.18,35
Replacement of arginine residue 1617 by glutamine
appears to interfere with the initiation of fast inactiva-
tion from the open state. Arginine 1617 is the outermost
charged residue in the S4 voltage sensor segment of
DIV, which is thought to initiate channel inactivation
through a conformational change.36 In the crystal struc-
ture of the single domain bacterial channel NaChBac,
the outermost arginine of S4 interacts with the nega-
tively charged glutamate residue in segment S1 in the
open state, and the negatively charged aspartate in seg-
ment S2 in the closed state.37 Loss of the positively
charged arginine by p.Arg1617Gln would disrupt these
electrostatic interactions, consistent with the observed
defect in coupling of activation and inactivation
(Fig. 2C). We also observed a small depolarizing shift in
the voltage dependence of inactivation due to
p.Arg1617Gln. The alterations in V1/2 and the slope of
the steady-state inactivation curve are consistent with
impaired allosteric interactions between the DIV-S1 sen-
sor segment that initiates activation and the DIV-S4 sen-
sor segment that initiates inactivation.
Comparison with previously described
pathogenic mutations of SCN8A
Through different effects on intramolecular interactions,
the recurrent mutations of Arg1617 and Arg1872 lead to
disruption of channel inactivation in 15 independent
patients. Along with the original mutation, p.Asn1768Asp,
this work indicates that impaired inactivation of Nav1.6 is
the predominant pathogenic mechanism in EIEE13. A con-
trasting mechanism, premature channel activation, was
Table 2. Biophysical properties of SCN8A mutants.
Peak Current
(pA/pF) n
Persistent Activation (mV) Inactivation (mV)
Ratio (Ip/Ipeak) n V1/2 k n V1/2 k n
WT 101  15 30 1.8  0.4 8 13.3  0.5 7.3  0.2 30 61.5  1.1 8.0  0.4 19
Arg1872Leu 89  15 10 4.7  1.5* 6 17.9  1.2*** 6.7  0.4 10 60.0  1.3 7.5  0.8 10
Arg1872Trp 153  27† 21 2.7  0.4 11 14.2  1.4 7.2  0.4 21 61.4  1.6 8.6  0.6 18
Arg1872Gln 135  35 8 1.6  0.5 17 19.2  0.8*** 5.8  0.5** 8 53.5  0.5*** 7.9  0.3 18
Arg1617Gln 73  15 10 5.5  1.7* 5 17.1  2.0* 7.8  0.3 10 52.6  1.7*** 12.5  0.6*** 8
Values represent mean  SEM, n = number of cells, V1/2, voltage of half-maximal activation or inactivation; k, slope factor. Significance was
determined by unpaired Student’s t test: *P < 0.05 versus WT, **P < 0.005 versus WT, ***P < 0.0005 versus WT, or Mann–Whitney test,
†P < 0.05 versus WT.
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observed for two mutations located in transmembrane seg-
ments of domain II, pThr767Ile and p.Asn984Lys.6,9 The
other two functionally characterized SCN8A mutations
caused reduction in peak current density (p.Gly1451Ser)6
and decreased protein stability (p.Arg223Gly)7; the role of
these effects in neuronal hyperexcitability is unclear.
Figure 3. Biophysical effects of the missense mutation p.Arg1617Gln in Nav1.6. (A) Representative traces of families of Na currents from ND7/23
cells transfected with the indicated Nav1.6 cDNA. (B) Averaged current–voltage (I-V) relation for cells expressing WT and p.Arg1617Gln. Peak
currents were normalized to cell capacitance. (C) Average fast time constant obtained from single exponential fits to macroscopic current decays
as a function of voltage (mV). (D) Representative traces of normalized currents evoked by a depolarizing step to 20 mV from a holding potential
of 120 mV illustrate significant delay in macroscopic current decay in p.Arg1617Gln (blue) compared to WT (black). (E) Representative
normalized current traces recorded during a 100-msec depolarizing pulse from 120 mV to 0 mV illustrating the presence of elevated persistent
sodium current. (F) Voltage dependence of channel activation. (G) Voltage dependence of steady-state inactivation. (H). Representative
inactivation traces recorded after a 1-sec prepulse of 100 mV (larger amplitude) and 45 mV (smaller amplitude). Smooth lines in (F) and (G)
correspond to the least squares fit when average data were fit to a single Boltzmann equation. Data are mean  SEM. Statistical significance:
*P < 0.05. Black, wild type; blue, p.Arg1617Gln.
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Functional alterations of SCN8A and clinical
severity
There is considerable heterogeneity in the clinical features
of patients with mutation of Arg1872, even among
patients with identical mutations (Table S1). With respect
to age of onset, intellectual disability, and motor function,
the least severe course of disease was seen in patients with
p.Arg1872Gln. More severe impairment, extending to
inability to initiate purposeful movement and one case of
SUDEP, was seen in the patients with p.Arg1872Leu and
p.Arg1872Trp. p.Arg1872Gln led to bradycardia in patient
3, consistent with our recent observation of cardiac
arrhythmia in a mouse model of EIEE13 (Frasier et al.,
unpubl. ms.). The expression of Nav1.6 in cardiomy-
ocytes38 may contribute to risk of SUDEP in EIEE13
patients.
The five previously described patients with the
p.Arg1617Gln mutation also displayed considerable clini-
cal heterogeneity, with seizure onset between 3 and
12 months of age, and variation in drug responses.5 One
patient became nonambulatory and one had SUDEP.
The features of patients with mutations of Arg1617 and
Arg1872 exhibit considerable overlap, consistent with
their shared effect on channel inactivation. Seizure onset
within the first month is more common in patients with
mutations of Arg1872, but there is no difference in the
proportion of patients whose seizures are refractory to
drug treatment, or in the frequency of nonambulatory
status. The variation within each group appears as great
as the difference between groups. Variation between
patients with identical mutations may be accounted for
by differences in genetic background, including genetic
variation in other channel genes,39 as well as stochastic
variation during the development of the nervous system.
The course of drug treatment itself may influence clinical
outcome.5
Development of targeted therapy for EIEE13
Sodium channel blockers have some efficacy in this
patient population, presumably by countering the effects
of gain-of-function mutations causing channel hyperactiv-
ity (Tables 1, S1). This beneficial response contrasts to
the response of patients with Dravet syndrome (EIEE6),
in which the effects of loss-of-function mutations of
SCN1A are exacerbated by administration of sodium
channel blockers. Unfortunately, response to antiepileptic
drugs in EIEE13 is often transient. The development of
Nav1.6-specific channel blockers has been hampered by
the structural similarity among members of the voltage-
gated sodium channel gene family. A mouse epilepsy
model with impaired inactivation of Scn2a was effectively
treated with the cardiac drugs ranolazine and GS967,
which are somewhat selective inhibitors of persistent
sodium current.40 Activation of potassium channels to
compensate for sodium channel hyperactivity is another
potential approach.
Recurrent missense mutations at SCN8A residues
Arg1617 and Arg1872 result in elevated activity of Nav1.6
as a result of impaired channel inactivation. This work
confirms the important role of gain-of-function muta-
tions in EIEE13 and demonstrates that impaired channel
inactivation is a prominent pathogenic mechanism.
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Appendix1: Clinical Descriptions
Patient 1 experienced onset of generalized tonic–clonic sei-
zures at 2 weeks of age that were refractory to treatment. A
vagus nerve stimulator placed at 4 years of age reduced sei-
zure frequency. Phenytoin reduced seizures, while carba-
mazepine, oxcarbazepine, lamotrigine, and topirimate were
not effective. The patient was able to stand and walk with
support at 12–15 months, but regressed and became non-
ambulatory, with generalized hypotonia at 5 years, con-
tractures and spasticity at 13 years, and generalized
hypertonia and spastic quadriplegia at 16 years. MRI
ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 121
J. L. Wagnon et al. Recurrent SCN8A Mutations in Epilepsy
revealed moderate cerebellar and mild cerebral atrophy. At
17 years, the patient is nonverbal with severe intellectual
disability.
Patient 2 experienced three prolonged seizures between
6 and 8 weeks of age. No abnormalities were detected by
MRI or prolonged EEG. She responded well to levetirac-
etam and topiramate for 2 months before the return of
generalized tonic–clonic seizures with stiffening of the
extremities, twitching, and eye fluttering. Seizures were
often accompanied by apnea and oxygen desaturation that
resolved after the seizure. The patient was transitioned
from levetiracetam and topirimate to oxcarbazepine and
lamotrigine with good response until seizure frequency
increased at 11 months of age. With the addition of val-
proate and clonazepam, seizures were well controlled
from 12 months to the current age of 18 months. Devel-
opmental delay was mild until 11 months, when increased
seizure frequency resulted in acute developmental regres-
sion including loss of head and trunk control, loss of eye
contact, and placement of a feeding tube. Control of sei-
zures at 12 months of age resulted in improvement
including regained eye contact and head control and the
ability to sit with support.
Patient 3 experienced seizures beginning at 4 months
of age, usually during sleep or on waking, accompanied
by tonic posturing of the head and severe bradycardia,
followed by flexing of the arms and extension of the legs.
Levetiracetam and zonisamide controlled seizures for
1 month before daily seizures reoccurred. Elevating zon-
isamide reduced seizures but caused severe (nonepileptic)
encephalopathy, reversible upon lowering zonisamide.
Addition of phenytoin reduced seizures to ≤1 per week.
Gradual reduction of phenytoin resulted in increased sei-
zure frequency. After an episode of status epilepticus at
19 months, seizure frequency stabilized at 5–10 per day,
with development of asymmetric and absence seizures.
Complete seizure control was obtained at 20 months with
phenytoin and levetiracetam, and continued through the
current age of 24 months. EEG was normal initially, but
6 weeks after seizure onset a hypofunctional area was
detected in the left temporal lobe, from which abundant
spike-and-wave configurations and polyspikes emerged.
EEGs at 6 and 9 months showed severe diffuse
encephalopathy and multifocal epileptic discharges with-
out hypsarrhythmia. MRI at 12 months showed a slightly
underdeveloped cortex. Development was normal prior to
seizure onset. Speech arrested at 10 months of age. While
seizures were partially controlled between 11 and
17 months of age, he began sitting and walking with sup-
port. After status epilepticus at 19 months there was
regression, but by 24 months he recovered unassisted
walking and improved social interaction without
improvement in development of speech.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Substitution of tryptophan for Arg1872 of
Nav1.6 does not impair coimmunoprecipitation of inter-
acting proteins. (A) Gb2, (B) GFP-tagged sodium channel
subunit b1, (C) myc-tagged FGF14b.
Table S1. Phenotypes of 10 individuals with amino acid
substitutions at arginine residue 1872.
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